New drug combo shows promise for Hard-to-Treat ovarian cancer

NCT ID NCT04606914

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a combination of the targeted drug mirvetuximab soravtansine and the chemotherapy carboplatin as a first treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific marker (folate receptor alpha). About 70 participants will receive the drugs before and after surgery to remove visible tumors. The goal is to see if this approach improves how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mirvetuximab soravtansine (a targeted drug that delivers chemotherapy to cancer cells with a specific marker) combined with carboplatin (a standard chemotherapy)
What this could lead to: If successful, this could offer a more effective first-line treatment option for women with advanced ovarian cancer that has a specific marker (folate receptor alpha).
What could go wrong: This is a small, early-phase (phase 2) study with only 70 participants, so results may not apply to all patients. The drug combination may cause side effects, and it is not yet known if it improves survival compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube disorder ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE OVARIAN CANCER PRIMARY PERITONEAL CANCER

Contacts and locations

Locations

Allegheny Health Network
RECRUITING

Pittsburgh, Pennsylvania, 15224, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Ohio State University
RECRUITING

Columbus, Ohio, 43026, United States
University of Alabama at Birmingham Womens & Infants Center
RECRUITING

Birmingham, Alabama, 35233, United States
University of California San Francisco
RECRUITING

San Francisco, California, 94158, United States
University of Minnesota - Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States
University of Mississippi Medical Center
RECRUITING

Oxford, Mississippi, 36607, United States
University of Oklahoma
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
University of Virginia
RECRUITING

Richmond, Virginia, 23219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.